Monopar Therapeutics (NASDAQ:MNPR) Now Covered by Analysts at Piper Sandler

Investment analysts at Piper Sandler began coverage on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report issued on Friday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $72.00 price target on the stock. Piper Sandler’s target price would suggest a potential upside of 184.02% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Rodman & Renshaw started coverage on shares of Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 target price for the company. HC Wainwright increased their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $25.35 on Friday. The firm has a market capitalization of $133.80 million, a price-to-earnings ratio of -12.87 and a beta of 1.23. Monopar Therapeutics has a one year low of $1.54 and a one year high of $38.50. The business has a fifty day moving average price of $21.84 and a 200-day moving average price of $10.74.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.09. On average, equities research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average price of $16.25 per share, with a total value of $25,187.50. Following the acquisition, the chief financial officer now owns 1,550 shares in the company, valued at approximately $25,187.50. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.